Zelluna Immunotherapy Overview

  • Founded
  • 2016
  • Status
  • Private
  • Employees
  • 16
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $8.28M
Latest Deal Amount
  • Investors
  • 3

Zelluna Immunotherapy General Information


Operator of a biopharmaceutical company intended to develop T-cell receptor (TCR) based cancer immunotherapy. The company's primary focus is to develop a portfolio of tumor-specific TCRs to guide NK cells with the aim to induce cancer responses that are safe, efficient and durable, enabling patients who are currently lacking efficient treatments to get their required treatments, from a wide range of advanced technologies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Oslo Cancer Cluster Innovation Park
  • Ullernchausséen 64
  • 0379 Oslo
  • Norway
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Zelluna Immunotherapy Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 11-Jun-2020 $8.28M Completed Generating Revenue
1. Early Stage VC 01-Jan-2016 Completed Startup
To view Zelluna Immunotherapy’s complete valuation and funding history, request access »

Zelluna Immunotherapy Executive Team (6)

Name Title Board Seat Contact Info
Namir Hassan Ph.D Chief Executive Officer
Geir Christian Melen Chief Financial Officer & Director of Finance
Anders Holm Ph.D Chief Operating Officer & Head, Business Development
Arjan Roozen Chief Technology Officer
Hans Ivar Robinson Co-Founder & Chairman
You’re viewing 5 of 6 executive team members. Get the full list »

Zelluna Immunotherapy Board Members (6)

Name Representing Role Since
Anders Tuv Radforsk Investeringsstiftelse Board Member 000 0000
Bent Jakobsen Ph.D Self Board Member 000 0000
Gustav Gaudernack Self Board Member 000 0000
Hans Ivar Robinson Self Co-Founder & Chairman 000 0000
Hans-Peter Bøhn Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Zelluna Immunotherapy Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zelluna Immunotherapy Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Birk Venture Venture Capital Minority 000 0000 000000 0
Radforsk Investeringsstiftelse Limited Partner Minority 000 0000 000000 0
Ro Invest Venture Capital Minority 000 0000 000000 0
To view Zelluna Immunotherapy’s complete investors history, request access »